Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Sep 7;28(9):750-751.
doi: 10.1093/oncolo/oyad204.

Implications of Contact Days in the Treatment of Relapsed Refractory Diffuse Large B-Cell Lymphoma

Leyla Bojanini  1 , Neel Gupta  1 , Ali Raza Khaki  1
Affiliations
Comment

Implications of Contact Days in the Treatment of Relapsed Refractory Diffuse Large B-Cell Lymphoma

Leyla Bojanini et al. Oncologist. .

Abstract

This commentary remarks on a recently published study assessing clinic contact days for patients enrolled in the Canadian Cancer Trials Group LY.12 clinical trial.

PubMed Disclaimer

Conflict of interest statement

Neel Gupta is a consultant for Corvus and Atara. Ali Raza Khaki reported institutional research funding from 23andMe and Janssen, research collaboration with Tempus Labs, and consulting for Janssen (declined compensation). Leyla Bojanini indicated no financial relationships.

Comment on

References

    1. National Cancer Institute. Cancer stat facts: NHL — diffuse large B-cell lymphoma (DLBCL). https://doi.org/https://seer.cancer.gov/statfacts/html/dlbcl.html
    1. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-1808. 10.1182/blood-2017-03-769620 - DOI - PMC - PubMed
    1. Gupta A, Hay AE, Crump M, et al. Contact days associated with cancer treatments in the CCTG LY.12 Trial. Oncologist. 2023; 28(9):799-803. 10.1093/oncolo/oyad128 - DOI - PMC - PubMed
    1. Gupta A, O’Callaghan CJ, Zhu L, et al. Evaluating the time toxicity of cancer treatment in the CCTG CO.17 trial. JCO Oncol Pract. 2023;19(6):e859-e866. - PMC - PubMed
    1. Gupta A, Eisenhauer EA, Booth CM.. The time toxicity of cancer treatment. J Clin Oncol. 2022;40(15):1611-1615. 10.1200/jco.21.02810 - DOI - PubMed

MeSH terms